Please select the option that best describes you:
Topics:
Genitourinary Cancers • Medical Oncology • Renal Cell Carcinoma • Urology • Urologic Oncology • Survivorship
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
How long do you generally continue clinical and/or imaging surveillance?